Donated livers can be made biologically younger

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-14T16:55:35.436Z • Permanent link

Renowned surgeon Dr. David Fassett, a leading expert in liver transplantation, has been working closely with researchers at the University of California, Los Angeles (UCLA) to develop a groundbreaking technology that can make donated livers biologically younger. This innovative approach has the potential to significantly improve the lives of patients awaiting liver transplants. According to Dr. Fassett, the UCLA team has been exploring ways to enhance the regenerative capabilities of donated livers, with a focus on improving their function and lifespan. The researchers have been using a combination of cutting-edge technologies, including 3D printing and gene editing, to create liver tissue that can be used to repair damaged or diseased organs.

The technology, which is still in its early stages, has been tested on a small group of patients who have received liver transplants. Preliminary results have been promising, with many patients showing significant improvements in their liver function and overall health. The UCLA team is now working with the US Food and Drug Administration (FDA) to conduct further clinical trials and gather more data on the safety and efficacy of their technology. If successful, this technology could revolutionize the field of organ transplantation, providing new hope for thousands of patients worldwide.

The brainchild of Dr. Fassett and his team, this technology is the result of years of research and collaboration between scientists, clinicians, and engineers. The UCLA researchers have been working closely with companies such as Organovo, a leading developer of 3D-printed organs, to advance the field of regenerative medicine. The project has been funded by a combination of government grants and private investment, including a significant donation from the Bill and Melinda Gates Foundation.

The potential impact of this technology on the Biotech & Medical domain cannot be overstated. Companies such as United Therapeutics and Regeneron Pharmaceuticals, which are already working on regenerative medicine technologies, are likely to be major beneficiaries of this breakthrough. The development of biologically younger livers could also have significant implications for the organ transplantation industry as a whole, potentially reducing the need for repeated transplants and improving patient outcomes.

The research community is also likely to be closely watching the development of this technology, as it has the potential to advance our understanding of regenerative medicine and improve treatment options for a wide range of diseases and conditions. The FDA is also likely to play a key role in the regulatory approval process, working closely with the UCLA team to ensure that the technology meets the highest standards of safety and efficacy. As the technology continues to evolve, it will be important for policymakers to consider the potential implications for healthcare systems and the broader economy.

The development of biologically younger livers is part of a larger trend in regenerative medicine, which has been gaining momentum in recent years. Other companies, such as Ginkgo Bioworks and Cellular Biotechnology, are also working on regenerative medicine technologies, including 3D printing and gene editing. This trend is also being driven by advances in technology, including the development of new gene editing tools and the increasing availability of high-throughput sequencing data.